Adverum Biotechnologies, Inc.
https://adverum.com/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Adverum Biotechnologies, Inc.
Adverum, 4D Molecular Present Dueling Phase II Datasets In Wet AMD
The two biotechs each hope to offer an Eylea-sparing regimen to wet age-related macular degeneration patients with gene therapies that induce natural production of aflibercept.
Adverum Climbs Out Of Abyss With Promising Early Gene Therapy Data In Wet AMD
The Phase II LUNA study of ixo-vec showed a reduction in anti-VEGF use and stabilization of visual acuity and anatomic parameters that Adverum – and some analysts – called best in class.
Finance Watch: Alto, Fractyl Bring IPO Count To Four, So Far, In 2024
Public Company Edition: Alto Neuroscience and Fractyl Health grossed $128.6m and $110m, respectively, while FibroBiologics went public in a direct listing. Also, Vaxcyte grossed $862.5m in a follow-on offering, Immunocore grossed $350m in a note sale and Vera raised $287.5m.
4D Molecular Therapeutics Brings A New Dimension To Wet AMD
The eye disease gene therapy 4D-150 posted highly impressive Phase II data, prompting a near-doubling of the company’s market value.
Company Information
- Industry
- Pharmaceuticals
-
Pharmaceuticals
- Drug Delivery
-
Biotechnology
- Gene Therapy, Cell Therapy
- Large Molecule
- Other Names / Subsidiaries
-
- Annapurna Therapeutics SAS, Avalanche Biotechnologies, Inc.
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice